These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 34389513)

  • 21. The Cost-Effectiveness of Subcutaneous Semaglutide Versus Empagliflozin in Type 2 Diabetes Uncontrolled on Metformin Alone in Denmark.
    Ehlers LH; Lamotte M; Ramos MC; Sandgaard S; Holmgaard P; Kristensen MM; Ejskjaer N
    Diabetes Ther; 2022 Mar; 13(3):489-503. PubMed ID: 35187628
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cost-effectiveness of empagliflozin compared with liraglutide based on cardiovascular outcome trials in Type II diabetes.
    Ramos M; Ustyugova A; Hau N; Lamotte M
    J Comp Eff Res; 2020 Aug; 9(11):781-794. PubMed ID: 32573253
    [No Abstract]   [Full Text] [Related]  

  • 23. First-Line Therapy for Type 2 Diabetes With Sodium-Glucose Cotransporter-2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists : A Cost-Effectiveness Study.
    Choi JG; Winn AN; Skandari MR; Franco MI; Staab EM; Alexander J; Wan W; Zhu M; Huang ES; Philipson L; Laiteerapong N
    Ann Intern Med; 2022 Oct; 175(10):1392-1400. PubMed ID: 36191315
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cost-effectiveness of dapagliflozin (Forxiga®) added to metformin compared with sulfonylurea added to metformin in type 2 diabetes in the Nordic countries.
    Sabale U; Ekman M; Granström O; Bergenheim K; McEwan P
    Prim Care Diabetes; 2015 Feb; 9(1):39-47. PubMed ID: 24840612
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cost effectiveness of combination therapy with pioglitazone for type 2 diabetes mellitus from a german statutory healthcare perspective.
    Neeser K; Lübben G; Siebert U; Schramm W
    Pharmacoeconomics; 2004; 22(5):321-41. PubMed ID: 15061682
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cost-effectiveness of metformin plus vildagliptin compared with metformin plus sulphonylurea for the treatment of patients with type 2 diabetes mellitus: a Portuguese healthcare system perspective.
    Viriato D; Calado F; Gruenberger JB; Ong SH; Carvalho D; Silva-Nunes J; Johal S; Viana R
    J Med Econ; 2014 Jul; 17(7):499-507. PubMed ID: 24708176
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cost-effectiveness of dapagliflozin compared to DPP-4 inhibitors as combination therapy with metformin in the treatment of type 2 diabetes mellitus without established cardiovascular disease in Colombia.
    Lasalvia P; Gil-Rojas Y; García Á
    Expert Rev Pharmacoecon Outcomes Res; 2022 Sep; 22(6):955-964. PubMed ID: 35259045
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cost and clinical implications of diabetes prevention in an Australian setting: a long-term modeling analysis.
    Palmer AJ; Tucker DM
    Prim Care Diabetes; 2012 Jul; 6(2):109-21. PubMed ID: 22153888
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A cost-effectiveness analysis of pioglitazone plus metformin compared with rosiglitazone plus metformin from a third-party payer perspective in the US.
    St Charles M; Minshall ME; Pandya BJ; Baran RW; Tunis SL
    Curr Med Res Opin; 2009 Jun; 25(6):1343-53. PubMed ID: 19419339
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Are the cardiovascular and kidney benefits of empagliflozin influenced by baseline glucose-lowering therapy?
    Inzucchi SE; Fitchett D; Jurišić-Eržen D; Woo V; Hantel S; Janista C; Kaspers S; George JT; Zinman B;
    Diabetes Obes Metab; 2020 Apr; 22(4):631-639. PubMed ID: 31789445
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Long-Term Cost-Effectiveness Analyses of Empagliflozin Versus Oral Semaglutide, in Addition to Metformin, for the Treatment of Type 2 Diabetes in the UK.
    Ramos M; Cummings MH; Ustyugova A; Raza SI; de Silva SU; Lamotte M
    Diabetes Ther; 2020 Sep; 11(9):2041-2055. PubMed ID: 32700188
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Empagliflozin improves glycaemic and weight control as add-on therapy to pioglitazone or pioglitazone plus metformin in patients with type 2 diabetes: a 24-week, randomized, placebo-controlled trial.
    Kovacs CS; Seshiah V; Swallow R; Jones R; Rattunde H; Woerle HJ; Broedl UC;
    Diabetes Obes Metab; 2014 Feb; 16(2):147-58. PubMed ID: 23906415
    [TBL] [Abstract][Full Text] [Related]  

  • 33. EMPA-REG and Other Cardiovascular Outcome Trials of Glucose-lowering Agents: Implications for Future Treatment Strategies in Type 2 Diabetes Mellitus.
    Schernthaner G; Schernthaner-Reiter MH; Schernthaner GH
    Clin Ther; 2016 Jun; 38(6):1288-1298. PubMed ID: 27210264
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cost-effectiveness analysis of empagliflozin treatment in people with Type 2 diabetes and established cardiovascular disease in the EMPA-REG OUTCOME trial.
    Kansal A; Reifsnider OS; Proskorovsky I; Zheng Y; Pfarr E; George JT; Kandaswamy P; Ruffolo A
    Diabet Med; 2019 Nov; 36(11):1494-1502. PubMed ID: 31295358
    [TBL] [Abstract][Full Text] [Related]  

  • 35. SODIUM GLUCOSE COTRANSPORTER 2 AND DIPEPTIDYL PEPTIDASE-4 INHIBITION: PROMISE OF A DYNAMIC DUO.
    Lingvay I
    Endocr Pract; 2017 Jul; 23(7):831-840. PubMed ID: 28332871
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Combination therapy for patients with uncontrolled type 2 diabetes mellitus: adding empagliflozin to pioglitazone or pioglitazone plus metformin.
    Blevins T
    Expert Opin Drug Saf; 2015 May; 14(5):789-93. PubMed ID: 25789798
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cost effectiveness of adding dapagliflozin to insulin for the treatment of type 2 diabetes mellitus in the Netherlands.
    van Haalen HG; Pompen M; Bergenheim K; McEwan P; Townsend R; Roudaut M
    Clin Drug Investig; 2014 Feb; 34(2):135-46. PubMed ID: 24243529
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cost-Effectiveness of Empagliflozin in Patients With Heart Failure and Preserved Ejection Fraction.
    Zhou J; Liew D; Kaye DM; Zoungas S; Stub D
    Circ Cardiovasc Qual Outcomes; 2022 Oct; 15(10):e008638. PubMed ID: 36252135
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cost-effectiveness analysis of dapagliflozin versus glimepiride as monotherapy in a Chinese population with type 2 diabetes mellitus.
    Shao H; Zhai S; Zou D; Mir MU; Zawadzki NK; Shi Q; Liu S; Shi L
    Curr Med Res Opin; 2017 Feb; 33(2):359-369. PubMed ID: 27817216
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Empagliflozin/linagliptin single-pill combination therapy for patients with type 2 diabetes mellitus.
    Jain RK
    Expert Opin Pharmacother; 2017 Apr; 18(6):545-549. PubMed ID: 28375658
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.